Press Release from Artimplant's Nomination Committee

In advance of Artimplant's (STO:ARTIB) Annual Meeting of Stockholders on May 6, 2008, Artimplant's Nomination Committee has decided to propose that Ingemar Kihlstrom, Lennart Ribohn, Anna Malm Bernsten and Wenche Rolfsen be re-elected as members of the Board of Directors. Rickard Soderberg declines re-election. The Nomination Committee has also decided to propose Mats Lindquist as a new member.

Mats Lindquist is Vice President, Global Business Development, NovaQuest. NovaQuest is the Partnering Group of Quintiles Transnational. Quintiles is a global CRO (Contract Research Organisation) with its core activities focused on clinical development and commercialization of pharmaceutical products. Mats Lindquist is a non executive Board member of BioPhausia AB.

About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production, and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon(R), meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on March 11, 2008 at 08:45 AM.

Further information at www.artimplant.com where one also can subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

This information was brought to you by Cision http://newsroom.cision.com